Treatment Modality-Dependent Risk of Diabetic Ketoacidosis in Patients with Type 1 Diabetes: Danish Adult Diabetes Database Study

被引:16
作者
Hoshina, Sari [1 ,2 ]
Andersen, Gregers S. [2 ]
Jorgensen, Marit E. [2 ,3 ]
Ridderstrale, Martin [2 ,4 ]
Vistisen, Dorte [2 ]
Andersen, Henrik U. [2 ]
机构
[1] Tokyo Womens Med Univ, Dept Diabet Ctr, Sch Med, 8-1 Kawadacho, Tokyo 1628666, Japan
[2] Steno Diabet Ctr Copenhagen, Gentofte, Denmark
[3] Univ Southern Denmark, Natl Inst Publ Hlth, Odense M, Denmark
[4] Novo Nordisk AS, Clin Pharmacol, Soborg, Denmark
关键词
Diabetic ketoacidosis; Insulin pump therapy; Type; 1; diabetes; Epidemiology; SUBCUTANEOUS INSULIN INFUSION; QUALITY-OF-LIFE; MULTIPLE DAILY INJECTIONS; SEVERE HYPOGLYCEMIA; GLYCEMIC CONTROL; PUMP THERAPY; EUROPEAN-ASSOCIATION; CHILDREN; ADOLESCENTS; METAANALYSIS;
D O I
10.1089/dia.2017.0231
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Aims: The aim of this study was to evaluate the incidence rates of diabetic ketoacidosis (DKA) according to treatment modality in patients with type 1 diabetes (T1D) in Denmark, either multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII). Materials and Methods: A total of 20,902 T1D registered in the Danish Adult Diabetes Database were followed for an average of 5.4 years. Poisson regression analyses with risk time as offset were used to compare differences in rates of DKA between CSII and MDI. Model was adjusted for age, sex, diabetes duration, previous DKA events, and hemoglobin A(1c) (HbA(1c)). A modifying effect of number of CSII patients on the DKA rates was tested. Results: During 113,731 person-years, 3100 DKA events were registered (53 among CSII). CSII patients were younger (42.3 vs. 47.9 years), a larger proportion was female (59% vs. 43%), had a shorter diabetes duration (19 vs. 21 years), and a lower HbA(1c) (61.9 vs. 66.6mmol/mol). There was no significant difference in the incidence rate of DKA between CSII and MDI (rate ratio: 1.30, 95% confidence interval: 0.97-1.76). However, in clinics with at least 250 CSII patients, rates of DKA events were lower among CSII users, while the opposite was true for the smaller clinics (P=0.016). Conclusions: Delivery of CSII in large diabetes clinics with sufficient support and patient education may ensure that CSII treatment does not lead to an increased risk of DKA.
引用
收藏
页码:229 / 234
页数:6
相关论文
共 32 条
[1]   FREQUENCY OF DIABETIC-KETOACIDOSIS AND HYPOGLYCEMIC COMA DURING TREATMENT WITH CONTINUOUS SUBCUTANEOUS INSULIN INFUSION - AUDIT OF MEDICAL-CARE [J].
BENDING, JJ ;
PICKUP, JC ;
KEEN, H .
AMERICAN JOURNAL OF MEDICINE, 1985, 79 (06) :685-691
[2]   Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes [J].
Bergenstal, Richard M. ;
Tamborlane, William V. ;
Ahmann, Andrew ;
Buse, John B. ;
Dailey, George ;
Davis, Stephen N. ;
Joyce, Carol ;
Peoples, Tim ;
Perkins, Bruce A. ;
Welsh, John B. ;
Willi, Steven M. ;
Wood, Michael A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (04) :311-320
[3]   Quality of life in Danish children and adolescents with type 1 diabetes treated with continuous subcutaneous insulin infusion or multiple daily injections [J].
Birkebaek, N. H. ;
Kristensen, L. J. ;
Mose, A. H. ;
Thastum, M. .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 106 (03) :474-480
[4]   Continuous subcutaneous insulin infusion - A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes [J].
Boland, EA ;
Grey, M ;
Oesterle, A ;
Fredrickson, L ;
Tamborlane, WV .
DIABETES CARE, 1999, 22 (11) :1779-1784
[5]   A 2-yr national population study of pediatric ketoacidosis in Sweden: predisposing conditions and insulin pump use [J].
Hanas, Ragnar ;
Lindgren, Fredrik ;
Lindblad, Bengt .
PEDIATRIC DIABETES, 2009, 10 (01) :33-37
[6]   Insulin Pump Risks and Benefits: A Clinical Appraisal of Pump Safety Standards, Adverse Event Reporting, and Research Needs A Joint Statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group [J].
Heinemann, Lutz ;
Fleming, G. Alexander ;
Petrie, John R. ;
Holl, Reinhard W. ;
Bergenstal, Richard M. ;
Peters, Anne L. .
DIABETES CARE, 2015, 38 (04) :716-722
[7]   Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial [J].
Hoogma, RPLM ;
Hammond, PJ ;
Gomis, R ;
Kerr, D ;
Bruttomesso, D ;
Bouter, KP ;
Wiefels, KJ ;
de la Calle, H ;
Schweitzer, DH ;
Pfohl, M ;
Torlone, E ;
Krinelke, LG ;
Bolli, GB .
DIABETIC MEDICINE, 2006, 23 (02) :141-147
[8]   Frequency and Cost of Diabetic Ketoacidosis in Germany - Study in 12 001 Paediatric Patients [J].
Icks, A. ;
Strassburger, K. ;
Baechle, C. ;
Rosenbauer, J. ;
Giani, G. ;
Beyer, P. ;
Holl, R. W. .
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2013, 121 (01) :58-59
[9]   Comparison of continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI) in paediatric Type 1 diabetes: a multicentre matched-pair cohort analysis over 3 years [J].
Jakisch, B. I. ;
Wagner, V. M. ;
Heidtmann, B. ;
Lepler, R. ;
Holterhus, P-M. ;
Kapellen, T. M. ;
Vogel, C. ;
Rosenbauer, J. ;
Holl, R. W. .
DIABETIC MEDICINE, 2008, 25 (01) :80-85
[10]   National Register of patients with insulin pump treatment in the Czech Republic [J].
Jankovec, Z. ;
Cechurova, D. ;
Krcma, M. ;
Lacigova, S. ;
Zourek, M. ;
Rusavy, Z. .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2006, 74 :S135-S139